Unravel Biosciences Submits Clinical Study Applications for Rett and Pitt Hopkins Syndromes

Unravel Biosciences has submitted clinical study applications for its RVL-001 trials targeting Rett syndrome and Pitt Hopkins syndrome to the Colombian Health Regulatory Agency, INVIMA. These submissions, announced in a press release, are part of a pilot program allowing for priority review and fast track approval for rare diseases.

The trials are set to begin in early summer at the Universidad de Antioquia's Center for Technological Development in Medellin, Colombia. Designed as placebo-controlled, "n-of-1" trials, they aim to enroll 15 patients with Rett syndrome and 5 with Pitt Hopkins syndrome. Unravel's proprietary BioNAV™ platform identified RVL-001 as a promising therapeutic candidate for these conditions, which currently have limited treatment options.

Dr. Carolina Lesmes, the Principal Investigator of the RVL-001 studies, expressed readiness to initiate the trials, emphasizing the importance of assessing the safety and potential efficacy of RVL-001 for these rare neurogenetic disorders.